Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 68071-5277

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 68071-5277). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5277 9)

Label for Clopidogrel bisulfate 75 mg film-coated tablets by NuCare Pharmaceuticals, Inc., with a count of 90 tablets. The label shows NDC 68071-5277-9 and advises to see manufacturer's label for full ingredients. It includes storage instructions and safety warnings, with manufacturer locations in Hauppauge, NY, and Orange, CA.*

FDA Label Image

Figure1 (Clopidogrel Fig)

A horizontal bar chart titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel 75 mg Alone or with Proton Pump Inhibitors (PPIs)'. It depicts the effect of various proton pump inhibitors (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on the active metabolite AUC of Clopidogrel 75 mg, showing mean values and 90% confidence intervals relative to clopidogrel alone on the horizontal axis ranging from 0.4 to 1.4.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. Two lines compare patients on placebo plus aspirin versus clopidogrel plus aspirin, with the clopidogrel group showing a lower cumulative event rate. The graph includes a p-value indicating statistical significance and notes that other standard therapies were used as appropriate.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

This image shows two forest plots illustrating hazard ratios with 95% confidence intervals for Clopidogrel bisulfate 75 mg compared to placebo across various subgroups. Subgroups include age, gender, race, cardiac enzyme levels, diabetes, previous myocardial infarction or stroke, and medication use such as Heparin/LMWH, aspirin dose, GP IIb/IIIa antagonists, beta-blockers, and ACE inhibitors. Each plot indicates whether the data favors Clopidogrel or placebo.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A cumulative event rate graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing the percentage of death before first discharge over 28 days since randomization. The graph compares placebo and clopidogrel treatment groups, with placebo having 8.1% deaths (1845 deaths) and clopidogrel 7.5% deaths (1726 deaths), indicating a 7% proportional risk reduction (p=0.03). All patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A Kaplan-Meier curve comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days between placebo and clopidogrel groups. The graph shows a 9% proportional risk reduction with clopidogrel compared to placebo, with events occurring in 10.1% of placebo and 9.2% of clopidogrel patients.*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot chart titled 'Effects of Adding Clopidogrel to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study.' It shows odds ratios with 99% confidence intervals for various subgroups including gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, comparing Clopidogrel to placebo.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line chart showing the cumulative event rate (%) of fatal or non-fatal vascular events over months of follow-up (0 to 36 months). Two lines indicate event rates for Aspirin and Clopidogrel, with Clopidogrel generally showing a slightly lower cumulative event rate. A p-value of 0.045 is noted on the graph.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study,' comparing Clopidogrel and Aspirin across different qualifying conditions: Stroke, MI, PAD, and Overall. The x-axis denotes hazard ratios ranging roughly from 0.6 to 1.3, with points indicating hazard ratios and confidence intervals for each subgroup, showing if Clopidogrel or Aspirin is favored.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate showing its molecular framework with key functional groups, including a thiophene ring, a lactam ring, and an ester group attached to a chlorophenyl moiety, along with the bisulfate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.